Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
Haematologica (2012)
  • Judith E. Karp, Johns Hopkins University
  • Elizabeth Garrett-Mayer, Medical University of South Carolina
  • Elihu H. Estey, University of Washington
  • Michelle A. Rudek, Johns Hopkins University
  • B. Douglas Smith, Johns Hopkins University
  • Jacqueline M. Greer, Johns Hopkins University
  • D. Michelle Drye, Johns Hopkins University
  • Karen Mackey, Johns Hopkins University
  • Kathleen Shannon Dorcy, University of Washington
  • Steven D. Gore, Johns Hopkins University
  • Mark J. Levis, Johns Hopkins University
  • Michael A. McDevitt, Johns Hopkins University
  • Hetty E. Carraway, Johns Hopkins University
  • Keith W. Pratz, Johns Hopkins University
  • Douglas E. Gladstone, Johns Hopkins University
  • Margaret M. Showel, Johns Hopkins University
  • Megan Othus, University of Washington
  • L. Austin Doyle, Johns Hopkins University
  • John J. Wright, National Institutes of Health
  • John M. Pagel, University of Washington
Link
Disciplines
Publication Date
November 1, 2012
DOI
10.3324/haematol.2012.062539
Citation Information
Judith E. Karp, Elizabeth Garrett-Mayer, Elihu H. Estey, Michelle A. Rudek, et al.. "Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia" Haematologica Vol. 97 Iss. 11 (2012) p. 1736 - 1742
Available at: http://works.bepress.com/john-pagel/156/